Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients

Clinical Cancer Research

Volumn 7, Issue 1, 2001, Pages 127-135

  Nikitina, Ekaterina ^a   Clark, Joseph I ^a   Van Beynen, James ^a   Chada, Sunil ^b   Virmani, Arvind K ^c   Carbone, David P ^d   Gabrilovich, Dmitry I ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Introgen Therapeutics Inc   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; ADULT; AGED; ANIMALS; ANTIGENS, CD8; CARCINOMA, NON-SMALL-CELL LUNG; DENDRITIC CELLS; FEMALE; GENE EXPRESSION; HEAD AND NECK NEOPLASMS; HLA-A2 ANTIGEN; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; LUNG NEOPLASMS; MACROGLOBULINS; MALE; MICE; MIDDLE AGED; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035136173     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. p53: A frequent target for genetic abnormalities in lung cancer
2. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer
3. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features
4. High frequency of somatically acquired p53 mutations in small cell lung cancer cell lines and tumors
5. Somatic mutations and human breast cancer. A status report
6. TP53 tumor suppressor gene: A model for investigating human mutagenesis
7. Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung
8. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
9. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors
10. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
11. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells
12. Targeting p53 as a general tumor antigen
13. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide
14. p53, a potential target for tumor-directed T cells
15. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas
16. Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells
17. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells
18. Use of recombinant adenovirus for metabolic engineering of mammalian cells
19. Gene therapy for cancer: What have we done and where are we going?
20. The dendritic cell system and its role in immunogenicity
21. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
22. High efficiency adenovirus-mediated gene transfer to human dendritic cells
23. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination
24. Dendritic cells transduced with wild type p53 gene elicit potent antitumor immune responses
25. Complete subtyping of the HLA-A locus by sequence-specific amplification followed by direct sequencing or single-strand conformation polymorphism analysis
26. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium
27. Decreased antigen presentation by dendritic cells in patients with breast cancer
28. Protein synthesis-dependent cytoplasmic translocation of p53 protein after serum stimulation of growth-arrested MCF-7 cells
29. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer
30. Flow-cytometric determination of peptide class i complex formation-identification of p53 peptides that bind to HLA-A2
31. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class i peptide binding assay
32. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53
33. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck
34. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes
35. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: Implications for vaccine design
36. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
37. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells
38. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
39. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-α for use in cancer immunotherapy
40. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: Implications for live kidney cancer vaccines